Last reviewed · How we verify
NCT04192292: SSS
Study of Sulphonylurea Synergy With DPP4 Inhibitors
NA trial testing Sulfonylurea in Type 2 Diabetes in 30 participants. Completed in 2 December 2020.
2 December 2020
Quick facts
| Lead sponsor | University of Dundee |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 30 |
| Start date | 8 October 2019 |
| Primary completion | 2 December 2020 |
| Estimated completion | 2 December 2020 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Sulfonylurea — full drug profile →
- DPP4 Inhibitor — full drug profile →
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
University of Dundee
Who can join
Adults 40 to 80, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Study of Sulphonylurea Synergy with DPP4 Inhibitors (SSS Study) will establish whether a very low dose of sulphonylurea will have a synergistic role on augmentation of insulin secretion when given in combination with a DPP4 inhibitor as a primary outcome. The study will recruit 30 patients with type 2 diabetes mellitus controlled with no treatment or metformin monotherapy with an HbA1c \<64mmol/mol (\<8%). In this unblinded, randomised physiological study, participants will receive four 14-day intervention blocks: low dose sulphonylurea alone, DPP4 inhibitor alone, low dose sulphonylurea + DPP4 inhibitor or no treatment change. The primary outcome will be assessed through evaulation of insulin secretion and sensitivity at mixed meal test at the end of each treatment block. Glycaemic variability on continuous glucose monitoring for each intervention block will be evaluated as a secondary outcome. In addition, the primary outcome will be evaulated for KCNJ11 genotype as an additional secondary outcome.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
57<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes.
· 2021 · cited 11× · PMID 34468792 · DOI 10.1007/s00125-021-05519-y -
Low-Dose Sulfonylurea Plus DPP4 Inhibitor Lower Blood Glucose and Enhance Beta-Cell Function Without Hypoglycemia.
Cordiner RLM, Bedair K, Mari A, Pearson E. · · 2024 · cited 2× · PMID 38267622 · DOI 10.1210/clinem/dgae033
Verify or expand the search:
- PubMed search for NCT04192292
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sulfonylurea
Trials testing the same drug.
- NCT05214573 — Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk · completed
- NCT03921242 — Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease · completed
- NCT03936023 — Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims · completed
- NCT03936062 — Replication of the TECOS Diabetes Trial in Healthcare Claims · completed
- NCT03936036 — Replication of the CARMELINA Diabetes Trial in Healthcare Claims · completed
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other University of Dundee trials
Trials by the same sponsor.
- NCT06435156 — Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes · Phase 2 · recruiting
- NCT05582798 — Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function · Phase 4 · completed
- NCT04419805 — Single Palatal Temporary Anchorage Device for Anterior Open Bite · NA · unknown
- NCT03747107 — Pharmacist and Data Driven Quality Improvement in Primary Care · completed
- NCT04817332 — STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19 · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04192292 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Dundee
- Last refreshed: 4 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04192292.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing